News

FDA Panel Vote on Peptides: What Eased Restrictions Mean for Semaglutide Compounding and Online Access
The FDA's advisory panel voted to ease restrictions on certain peptides, potentially expanding access to compounded semaglutide and other GLP-1 drugs Read more...
Retatrutide Compounding Loophole: FDA Panel Vote and Pharmacy Access vs. GLP-1 Shortage Restrictions
Retatrutide's weight-loss promise has outpaced FDA approval, creating a compounding loophole. As the agency weighs a panel vote, pharmacies and Read more...
Aspen's Generic Semaglutide in Canada: A Regulatory Precedent for Retatrutide Compounding Access
Aspen Pharmacare's generic semaglutide approval in Canada may set a regulatory precedent for compounded retatrutide, a triple-agonist peptide under Read more...
Retatrutide Compounding Under FDA Scrutiny After MedPage Today Investigation
A MedPage Today investigation into compounded retatrutide has drawn FDA attention, raising safety and regulatory questions for users of research Read more...
FDA Tightens Screws on Semaglutide Compounding: What It Means for Online Peptide Buyers
FDA enforcement against compounded semaglutide is intensifying, raising risks for online peptide buyers. This article breaks down the latest actions Read more...